Patient enrolment completed for fruquintinib’s Phase II study in non-small cell lung cancer
10-Mar-2015 -
Chi-Med nnounces that Hutchison MediPharma Limited (HMP) has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung cancer (NSCLC) patients in China. The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP’s ...
fruquintinib
non-small cell lung cancer
phase II studies